Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

OVERVIEW

Approximately 60% to 70% of patients with metastatic colorectal cancer (mCRC) who undergo successful liver resection will go on to develop further metastatic disease resulting in death within 2 years of surgery. For these patients, and for those with unresectable mCRC, chemotherapy using cytotoxic and/or targeted therapies are the only remaining treatment options. The primary mechanisms of action for targeted therapies include angiogenesis inhibition, via blocking vascular endothelial growth factor (VEGF) activity, or epidermal growth factor receptor (EGFR) inhibition. This comprehensive archived webcast will provide the most current science on the mechanisms of action of targeted therapy agents, patient populations that will and will not respond to treatment, the ability to differentiate the features of both class and mechanistic effects, and the knowledge to interpret survival data from clinical trials. Additional topics to be covered include: how to best premedicate patients if needed, effective strategies to monitor patients for drug interactions and treatment adherence, methods to guide the timing of continued therapy, and appropriate measures to prevent and manage side-effects and toxicities.

GOAL

This webcast archive will provide pharmacists with the most up-to-date information on current and emerging treatment options for patients with mCRC, best approaches for pharmacists to optimize therapy with regard to guiding therapy choices, adverse event pretreament and management, addressing accessibility and adherence issues, and pharmacoeconomic considerations.

TARGET AUDIENCE

This activity is designed for oncology, managed care, and specialty pharmacists. No prerequisites required.

LEARNING OBJECTIVES

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:

• DESCRIBE place in therapy for mCRC agents.
• IDENTIFY the mechanisms of action of current therapies for mCRC.
• FORMULATE strategies to overcome barriers to accessibility and adherence to mCRC therapies.
• DEMONSTRATE approaches to effectively manage both side-effects and toxicity reactions.

CREDIT DESIGNATION STATEMENT

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application- based program will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument  with a score of at least 70%. CE credit will be submitted to the NABP CE Monitor. UAN:  0064-0000-16-204-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Your CE credits will also be submitted electronically to NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Application
Published: May 13, 2016
Expires: May 13, 2017
Media: Internet
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes

HOW TO EARN CREDIT

Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES

As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

PARTICIPATING FACULTY

Jane E. Rogers, PharmD, BCOP
Clinical Pharmacy Specialist
GI Medical Oncology
University of Texas
MD Anderson Cancer Center
Houston, Texas
Dr Rogers reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Matthew Farber
Senior Director
Oncology Disease State
Walgreen Specialty Pharmacy
Deerfield, Illinois
Mr Farber reports holding stock in Walgreen's Boots Alliance.

OFF-LABEL PRODUCT DISCUSSION

In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

DISCLAIMER STATEMENT

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

ACTIVITY

The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5

AGENDA

Activity Overview and Goals
Jane E. Rogers, PharmD, BCOP

Overview of mCRC
Jane E. Rogers, PharmD, BCOP

Treatment of mCRC – Overview
Jane E. Rogers, PharmD, BCOP

Treatment of mCRC – Place in Therapy
Jane E. Rogers, PharmD, BCOP

The Role of the Pharmacist in Optimizing Therapy
Matthew Farber

Question and Answer Session
Matthew Farber and Jane E. Rogers, PharmD, BCOP
Conclusions

What you are about to see is a previously recorded live meeting.
Please note that only "home study" credit will be awarded for participating in this archived presentation. No "live" credits are available.